Pharmaceuticals in Indonesia
Summary
Pharmaceuticals in Indonesia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Synopsis
Essential resource for top-line data and analysis covering the Indonesia pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Key Highlights
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
- The Indonesian pharmaceuticals market had total revenues of $7.2bn in 2016, representing a compound annual growth rate (CAGR) of 8.8% between 2012 and 2016.
- Some impetus market growth can be attributed to the introduction of reimbursement programs, such as Jamkesmas and the Family Hope Program (Program Keluarga Harapan (PKH), which increased access to medicines and insurance coverage from 26.1% in 2007, to 65% in 2011.
- The Indonesian market is still controlled by domestic companies that hold 70% of the market share compared to the 30% owned by multinationals.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Indonesia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Indonesia
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Indonesia pharmaceuticals market with five year forecasts
- What was the size of the Indonesia pharmaceuticals market by value in 2016?
- What will be the size of the Indonesia pharmaceuticals market in 2021?
- What factors are affecting the strength of competition in the Indonesia pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitiors in Indonesia's pharmaceuticals market?
- Executive Summary
- Market value
- Market value forecast
- Geography segmentation
- Market share
- Market rivalry
- Market Overview
- Market definition
- Market analysis
- Market Data
- Market value
- Market Segmentation
- Geography segmentation
- Market share
- Market Outlook
- Market value forecast
- Five Forces Analysis
- Summary
- Buyer power
- Supplier power
- New entrants
- Threat of substitutes
- Degree of rivalry
- Leading Companies
- PT Kalbe Farma Tbk
- Novartis AG
- Sanofi SA
- Macroeconomic Indicators
- Country data
- Methodology
- Industry associations
- Related MarketLine research
- Appendix
- About MarketLine
- List of Tables
- Table 1: Indonesia pharmaceuticals market value: $ billion, 2012–16
- Table 2: Indonesia pharmaceuticals market geography segmentation: $ billion, 2016
- Table 3: Indonesia pharmaceuticals market share: % share, by value, 2016
- Table 4: Indonesia pharmaceuticals market value forecast: $ billion, 2016–21
- Table 5: PT Kalbe Farma Tbk: key facts
- Table 6: PT Kalbe Farma Tbk: key financials ($)
- Table 7: PT Kalbe Farma Tbk: key financials (IDR)
- Table 8: PT Kalbe Farma Tbk: key financial ratios
- Table 9: Novartis AG: key facts
- Table 10: Novartis AG: key financials ($)
- Table 11: Novartis AG: key financial ratios
- Table 12: Sanofi SA: key facts
- Table 13: Sanofi SA: key financials ($)
- Table 14: Sanofi SA: key financials (€)
- Table 15: Sanofi SA: key financial ratios
- Table 16: Indonesia size of population (million), 2012–16
- Table 17: Indonesia gdp (constant 2005 prices, $ billion), 2012–16
- Table 18: Indonesia gdp (current prices, $ billion), 2012–16
- Table 19: Indonesia inflation, 2012–16
- Table 20: Indonesia consumer price index (absolute), 2012–16
- Table 21: Indonesia exchange rate, 2012–16
- List of Figures
- Figure 1: Indonesia pharmaceuticals market value: $ billion, 2012–16
- Figure 2: Indonesia pharmaceuticals market geography segmentation: % share, by value, 2016
- Figure 3: Indonesia pharmaceuticals market share: % share, by value, 2016
- Figure 4: Indonesia pharmaceuticals market value forecast: $ billion, 2016–21
- Figure 5: Forces driving competition in the pharmaceuticals market in Indonesia, 2016
- Figure 6: Drivers of buyer power in the pharmaceuticals market in Indonesia, 2016
- Figure 7: Drivers of supplier power in the pharmaceuticals market in Indonesia, 2016
- Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Indonesia, 2016
- Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Indonesia, 2016
- Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Indonesia, 2016
- Figure 11: PT Kalbe Farma Tbk: revenues & profitability
- Figure 12: PT Kalbe Farma Tbk: assets & liabilities
- Figure 13: Novartis AG: revenues & profitability
- Figure 14: Novartis AG: assets & liabilities
- Figure 15: Sanofi SA: revenues & profitability
- Figure 16: Sanofi SA: assets & liabilities
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook